News Column

Spark Therapeutics Elects Dr. Elliott Sigal to Board of Directors

February 14, 2014

Spark Therapeutics, a late-stage company developing gene-based medicines for a range of debilitating diseases, announced the appointment of Elliott Sigal, M.D., Ph.D., former director, executive vice president and chief scientific officer of Bristol- Myers Squibb, to its board of directors.

According to a release, Sigal led Bristol-Myers Squibb during its ascent as a biopharmaceutical leader and built one of the industry's most productive research and development organizations through his forward-thinking approach to innovation.

"We are excited and honored that Elliott; who is among the most respected leaders within the biopharmaceutical industry; will join us in our mission to develop one-time, curative therapies to treat debilitating diseases," said Jeffrey D. Marrazzo, co-founder, president and CEO. "Elliott's achievements in fostering R&D productivity will help us more quickly advance our pipeline of gene- based medicines through the clinic and, ultimately, to patients in need."

While at Bristol-Myers Squibb, Sigal is credited with bringing more than 14 new medicines to market to treat diseases such as cancer, mental illness, HIV/AIDS, hepatitis B, rheumatoid arthritis, and cardiovascular and metabolic disease, and simultaneously reducing the company's R&D expenses to less than half of its competitors. He has more than 25 years of combined experience in medicine, research and management, as well as vast genetic and personalized medicine expertise. Prior to Bristol-Myers Squibb, Sigal held positions at Syntex as a vice president of research and as CEO at genomics firm Mercator Genetics, where his team discovered the gene for hemochromatosis, a common disorder that leads to iron overload, diabetes and liver disease. He currently is a venture partner and senior advisor for New Enterprise Associates and is a consultant to biotechnology companies. In addition, he serves on the board of directors for Mead Johnson Nutrition Company and the Melanoma Research Alliance.

"Spark's promising clinical results, and its scientific team with unmatched expertise in the advancement of gene therapy, provide the ideal foundation for impacting the practice of medicine," said Dr. Elliott Sigal. "I am eager to join the Spark team to support their mission to treat patients who are suffering from serious genetic conditions."

Spark recently appointed Rogerio Vivaldi, M.D., M.B.A., former senior vice president and Head of Rare Diseases at Genzyme, a Sanofi company. Elliott and Rogerio join Spark's existing board:

-Steven M. Altschuler, M.D., chairman of the board of directors and chief executive officer and president of The Children's Hospital of Philadelphia;

-Thomas J. Todorow, executive vice president and chief financial officer of The Children's Hospital of Philadelphia;

-Arthur Dantchick, managing director and member of the Management Committee of Susquehanna International Group;

-Sharad Mansukani, M.D., a practicing ophthalmologist and reimbursement strategist; vice chairman, HealthSpring; strategic advisor to the board, Cigna; and former senior advisor to the Administrator of the Centers for Medicare and Medicaid Services (CMS); and

-Jeffrey D. Marrazzo, co-founder, president and CEO of Spark Therapeutics.

The board expansion is part of Spark's strategy to continue building out its executive leadership team as it advances additional programs to the clinic and prepares to complete development of its Phase 3 clinical program and advance the industry's deepest pipeline of adeno-associated virus (AAV) vectors.

More Information:

www.sparktx.com/pioneering-leadership/board-directors

www.sparktx.com

((Comments on this story may be sent to newsdesk@closeupmedia.com))


For more stories covering the world of technology, please see HispanicBusiness' Tech Channel



Source: Health & Beauty Close - Up


Story Tools